Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$0.09
-8.0%
$0.10
$0.03
$0.14
$23.92M0.9555,995 shs42,487 shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$1.45
+3.6%
$1.32
$1.05
$8.79
$97.99M-0.11204,297 shs145,674 shs
Immunic, Inc. stock logo
IMUX
Immunic
$0.93
-0.9%
$0.83
$0.56
$2.11
$89.25M1.381.07 million shs668,229 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$3.10
+14.8%
$2.48
$0.81
$3.15
$116.59M-0.09145,910 shs799,881 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.00%-7.91%-7.26%-12.21%-38.67%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.00%0.00%+13.28%+14.17%+144,999,900.00%
Immunic, Inc. stock logo
IMUX
Immunic
0.00%-16.83%+27.78%-19.00%-34.86%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
0.00%+12.73%+6.90%+127.52%+152.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
1.2736 of 5 stars
0.05.00.00.02.81.70.0
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.3381 of 5 stars
3.60.00.00.00.02.51.3
Immunic, Inc. stock logo
IMUX
Immunic
2.9686 of 5 stars
3.62.00.00.03.22.50.6
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.1726 of 5 stars
3.55.00.00.03.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.00
N/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.25
Buy$9.00520.69% Upside
Immunic, Inc. stock logo
IMUX
Immunic
3.29
Buy$7.50705.15% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00125.81% Upside

Current Analyst Ratings Breakdown

Latest CHUC, OKYO, IMUX, and CLYM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/6/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$10.00
6/5/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $10.00
5/23/2025
Immunic, Inc. stock logo
IMUX
Immunic
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $5.00
5/22/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/22/2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$7.00
5/16/2025
Immunic, Inc. stock logo
IMUX
Immunic
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/5/2025
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$8.49M2.82N/AN/A($0.01) per share-9.20
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.15 per shareN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A$0.20 per shareN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.16) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
-$4.16M-$0.01N/AN/A-55.89%N/A-104.63%8/18/2025 (Estimated)
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$73.90M-$2.38N/AN/AN/AN/A-43.95%-42.94%8/13/2025 (Estimated)
Immunic, Inc. stock logo
IMUX
Immunic
-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$4.71MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)

Latest CHUC, OKYO, IMUX, and CLYM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2025
Immunic, Inc. stock logo
IMUX
Immunic
-$0.19N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.19N/AN/AN/AN/AN/A
5/29/2025Q4 2024
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/A-$0.01N/A-$0.01N/A$1.78 million
5/15/2025Q1 2025
Immunic, Inc. stock logo
IMUX
Immunic
-$0.25-$0.25N/A-$0.25N/AN/A
5/14/2025Q1 2025
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.15-$0.31-$0.16-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/AN/AN/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/A
0.51
0.06
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
14.25
14.25
Immunic, Inc. stock logo
IMUX
Immunic
N/A
0.74
0.74
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
0.40
0.40

Institutional Ownership

CompanyInstitutional Ownership
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
7.80%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
Immunic, Inc. stock logo
IMUX
Immunic
51.82%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
20.90%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.80%
Immunic, Inc. stock logo
IMUX
Immunic
4.60%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
40259.95 million205.62 millionNot Optionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
967.58 million67.04 millionN/A
Immunic, Inc. stock logo
IMUX
Immunic
7095.82 million91.41 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
737.61 million22.39 millionNot Optionable

Recent News About These Companies

OKYO Slides Despite Fresh R&D Funding

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charlie's stock logo

Charlie's OTCMKTS:CHUC

$0.09 -0.01 (-8.00%)
As of 08/1/2025 03:35 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$1.45 +0.05 (+3.57%)
As of 08/1/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Immunic stock logo

Immunic NASDAQ:IMUX

$0.93 -0.01 (-0.91%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.94 +0.01 (+0.81%)
As of 08/1/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$3.10 +0.40 (+14.81%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.19 +0.09 (+2.90%)
As of 08/1/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.